Join        Login             Stock Quote

Stock Buybacks Review: CTSH, HSIC, CELG, MMC, And PFG

 August 22, 2011 01:09 PM

Cognizant Technology Solutions Corp. (Nasdaq:CTSH) – Stock Favorable

On August 19, the company's board of directors authorized the expansion of its existing share repurchase program by $300 million, bringing the total authorization under the current repurchase program to $600 million.

The current announcement was preceded by announcements of stock repurchases of $150 million in March 2011, and of $150 million in December 2010.

During the three months ended June 30, 2011, the company repurchased $96.1 million of its class A common stock under the stock repurchase program. Announcement of the expansion of its existing share repurchase program couldn't have come at a better time, as the company's share price fell to a new 52-week low of $54.46 on Friday.

[Related -Celgene Corporation (NASDAQ:CELG): Why Should You Invest In Celgene In 2014?]

Analysts' one year consensus target price estimates range from a low of $74 to a high of $100. The consensus is $87. Given that in the last four quarters the company's reported EPS exceeded analysts' estimates and that the consensus EPS forecast for 2011 has increased over the past month from $2.76 to $2.80, I view the stock favorably.

Henry Schein Inc. (Nasdaq:HSIC) – Stock Favorable

On August 18, the company's board of directors authorized the repurchase of up to $200 million of shares of the company's common stock. The company added that the program is in addition to the $100 million repurchase program announced in November 2010, which has been fully executed. At present, Henry Schein has approximately 91 million shares outstanding and the new authorization represents around 3.5 percent of shares outstanding at the current stock price.

[Related -Cognizant Technology Solutions Corp (CTSH): How Penetration Rates Are Faring?]

During 2007–10, the company's outstanding shares have increased from 89.6 million to 91.94 million, so it is appropriate that the company reduce its outstanding shares through repurchases.

Since announcing Q2 results on August 3, 2011, the company's share price has come down to $60.24 from $65.29 on concerns that future growth in key dental and veterinary businesses is likely to be impacted by recent signs of slowing in consumer spending and in the overall economy. However, in the last four quarters, the company's reported EPS exceeded analysts' estimates. So, I view the stock favorably.

Celgene Corporation (Nasdaq:CELG) - Stock Favorable

On August 18, the company's board of directors authorized the repurchase of up to an additional $2 billion of the company's common stock.

Next Page >>12
iOnTheMarket Premium


Comments Closed

rss feed

Latest Stories

article imagePick a Valid Strategy, Stick With It

I’m not going to argue for any particular strategy here. My main point is this: every valid strategy is read on...

article imageHow to Prepare For A Correction Without Missing Out On Upside Potential

Recent market commentary is starting to remind me of the periods in 2000 and 2008 just before the bottom read on...

article imageBritain’s Boom Can Still Zoom

Don’t overthink the disconnect between strong UK GDP and wobbly UK stocks. Economic fundamentals should win read on...

article imageA Serious Red Flag

Stocks have stayed largely in reverse gear in the last week following weaker-than-expected earnings reports read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.